ORY-1001 exhibits various in vitro synergies in certain AML cell lines, including with ATRA, cytarabine, quizartinib, decitabine, azacitidine, vorinostat, the DOT1L inhibitor EPZ5676 and the BCL2 inhibitor ABT-737 [7]. Here, BCL2 is linked to acute myeloid leukemia.